Fracture risk after intralesional curettage of atypical cartilaginous tumors

J Orthop Surg Res. 2023 Nov 9;18(1):851. doi: 10.1186/s13018-023-04215-4.

Abstract

Introduction: The need for curettage of atypical cartilaginous tumors (ACT) is under debate. Curretage results in defects that weaken the bone potentially leading to fractures. The purpose of this study was to retrospectively determine postoperative fracture risk after curettage of chondroid tumors, including patient-specific characteristics that could influence fracture risk.

Methods: A total of 297 adult patients who underwent curettage of an ACT followed by phenolisation and augmentation were retrospectively evaluated. Explanatory variables were, sex, age, tumor size, location, augmentation type, and plate fixation. The presence of a postoperative fracture was radiologically diagnosed. Included patients had at least 90 days of follow-up.

Results: A total of 183 females (62%) were included and 114 males (38%), with an overall median follow-up of 3.2 years (IQR 1.6-5.2). Mean diameter of the lesions was 4.5 (SD 2.8) cm. Patients received augmentation with allograft bone (n = 259, 87%), PMMA (n = 11, 3.7%), or did not receive augmentation (n = 27, 9.1%). Overall fracture risk was 6%. Male sex (p = 0.021) and lesion size larger than 3.8 cm (p < 0.010) were risk factors for postoperative fracture.

Interpretation: Curettage of ACT results in an overall fracture risk of 6%, which is increased for males with larger lesions.

Keywords: ACT; Fracture risk; Orthopedic oncology.

MeSH terms

  • Adult
  • Bone Neoplasms* / pathology
  • Bone Neoplasms* / surgery
  • Curettage / adverse effects
  • Curettage / methods
  • Female
  • Follow-Up Studies
  • Fractures, Bone* / surgery
  • Humans
  • Male
  • Neoplasm Recurrence, Local
  • Retrospective Studies
  • Treatment Outcome